This study suggested that biotransformed PAC may be potent in reducing the progression of steatosis to NASH by mitigating cellular inflammation by suppressing TLR4/NF-κB and TLR4/MAPK inflammatory signaling [187]. The gene discussed is TLR4; the disease is metabolic dysfunction-associated steatohepatitis.